论文部分内容阅读
目的:对舒利迭治疗支气管哮喘的临床效果进行分析。方法:在2015年4月到2016年7月到我院进行支气管哮喘治疗的患者中选取62例,随机分为两组,分别为对照组(n=31)与治疗组(n=31),给予对照组患者长效β2-受体激动剂、抗IgE抗体、吸入糖皮质激素全身用激素、缓释茶碱、白三烯调节剂以及其他有利于减少全身激素剂量的药物,治疗组患者在对照组患者常规治疗的基础上,给予所有患者舒利迭吸入治疗,每天早晚各吸入一次,每次舒利迭的吸入量为1吸,避免哮喘发作期吸入舒利迭。两组患者均持续观察6周,分别在患者出院后的第2周、第4周、第6周对患者进行家庭随访,观察并记录两组患者的哮喘临床控制率、随访情况及对药物的不良反应。结果:两组患者治疗后,对照组患者治疗总有效率为87.1%,治疗组患者治疗总有效率为96.8%,两组之间的差异具有明显统计学意义(p<0.05),对照组患者的住院天数在4天到9天之间,平均住院天数为(6.2±1.8)天,治疗组患者的住院天数在2天到6天之间,平均住院天数为(3.5±1.2)天,两组之间的差异具有统计学意义(p<0.05)。对照组患者中共有4例分别在第2周与第4周后哮喘复发,复发率为12.9%,治疗组患者中仅有1例在第6周哮喘复发,复发率为3.2%,差异具有统计学意义在(p<0.05)。结论:使用舒利迭治疗支气管哮喘能够有效提高治疗成功率,缩短住院天数,并且能够有效降低复发率。
Objective: To analyze the clinical effect of Seretide on bronchial asthma. Methods: From April 2015 to July 2016, 62 patients were selected for treatment of bronchial asthma in our hospital and randomly divided into two groups: control group (n = 31) and treatment group (n = 31) Patients in the control group were treated with long-acting β2-agonist, anti-IgE antibody, systemic glucocorticoid inulin, sustained release theophylline, leukotriene modulators, and other medications that reduced systemic hormonal doses. Control group of patients based on conventional therapy, all patients given seretide inhalation therapy, inhaled daily morning and night, each inhalation of seretide as 1 suck, to avoid inhaling seretide during asthma attacks. The patients in both groups were observed for 6 weeks. The patients were followed up at 2 weeks, 4 weeks and 6 weeks after discharge respectively. The clinical control rate and follow-up of asthma in both groups were observed and recorded. Adverse reactions. Results: After treatment, the total effective rate of the control group was 87.1%, the total effective rate of the treatment group was 96.8%, the difference between the two groups was statistically significant (p <0.05), the control group The hospital stay was between 4 days and 9 days, with an average length of stay of 6.2 ± 1.8 days. The days of hospitalization in the treatment group ranged from 2 days to 6 days with an average length of stay of (3.5 ± 1.2) days and two The differences between groups were statistically significant (p <0.05). A total of 4 patients in the control group had asthma relapse after week 2 and week 4, respectively, with a recurrence rate of 12.9%. Only 1 patient in the treated group had a recurrence of asthma at week 6 with a recurrence rate of 3.2% The significance of learning (p <0.05). Conclusion: The use of seretide in the treatment of bronchial asthma can effectively improve the success rate of treatment, shorten the length of stay, and can effectively reduce the recurrence rate.